Gentian Diagnostics ASA, a fast-growing developer and manufacturer of innovative and efficient diagnostics for better treatment decisions, today was informed that the Oslo Stock Exchange has approved the companyâs application for transfer of its shares to Oslo Børs from Euronext Growth. Reference is made to the announcements 7 May 2021 regarding the application by Gentian for listing of its shares on Oslo Børs.
âŚ
Vis børsmeldingen
âWe made a promise to our shareholders when we were listed on Euronext Growth that we would aim for the main list when the company had matured. Iâm pleased that we now have achieved this milestone, and that we have access to a high-quality investor base as we work towards our ambitious targets of long-term growth and value creation,â says Hilja Ibert, CEO of Gentian Diagnostics.
In an updated investor presentation published 18 June 2021, the company outlined the market potential and roadmap for its portfolio of high-impact diagnostic tests. The long-term ambition is to generate an estimated annual revenue of NOK 1 billion in 5-7 years, up from NOK 79 million in 2020.
Gentianâs portfolio of diagnostic tests contributes to early disease detection and faster availability of clinically relevant information, which lead to better treatment decisions. In addition, they contribute to improve laboratory productivity and cost-efficiency by leveraging PETIA technology, which enable 3-10x higher throughput than traditional immunoassay platforms. The tests target several large and growing disease areas such as infections and inflammation, kidney failure and congestive heart failure. Gentian has four established products, one product in market development, and two products in development with launches scheduled for Q4 2021 and Q1 2022, respectively. Gentian also has three undisclosed biomarkers in exploration and âproof of conceptâ phases.
âWe have a diversified portfolio of tests, providing a solid foundation for growth and value creation. To deliver on our ambition, we aim to bring one additional product to market per year and expand market access through achieving additional regulatory approvals and commercial partners,â says Ibert.
The company has the pleasure of inviting to a virtual presentation on Thursday 24 June 2021 at 10:00-11.00 am CEST. Gentianâs CEO Hilja Ibert, CSO Erling Sundrehagen and CFO Njaal Kind will present the company followed by a Q&A session. Join the online presentation via the following link:
https: https://streams.eventcdn.net/gentian/company-presentation/
For further information, please contact:
Hilja Ibert, CEO
[email protected]
+47 919 05 242 (mobile)
Njaal Kind, CFO
[email protected]
+47 919 06 525 (mobile)
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures high-quality, in vitro diagnostic reagents. Gentianâs expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China. For more information, please visit www.gentian.com.
Kilde
